Business
InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"\nResults confirm improvements in cognitive function, memory and locomotor activity\nAchieved statistical significance in certain behavioral assessments\nAdditional molecular analyses ongoing to elucidate INM-901 mechanisms of action\n\nVancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease (\"AD\") study of INM-901 which confirms previously reported findings from a short-term (3 months of dosing) pilot study, as disclosed in the Company's prior press release dated April 4, 2024.\nSimilar to the short-term pilot study, this long-term dosing study was conducted using the 5xFAD amyloidosis model with extended dosing duration and increased sample size as compared to the short-term study. This long-term study had four groupings:\n\nUntreated disease-free group;\nINM-901-treated disease-free group;\nPlacebo-treated Alzheimer's Disease (amyloidosis) group; and\nINM-901-treated Alzheimer's Disease (amyloidosis) groups with two dosing levels.\n\nIt is important to note that disease severity increases with advancing age in this preclinical amyloidosis model such that groups in the long-term study had more advanced AD than those in the previous short-term pilot study.\nThe study included an assessment of several behavioral criteria across the four study groupings:\n\nNovel Object Recognition Test evaluating cognitive function and memory;\nOpen Field Test evaluating general locomotor activity level;\nElevated and Zero Maze Tests measuring anxiety-related behavior;\nBarnes Maze Test measuring spatial learning and memory; and\nAcoustic Startle Test measuring sound awareness.\n\nAll assessments of the INM-901-treated AD groups showed a positive trend towards behaviour similar to the untreated disease-free group, with most assessments demonstrating a clear dose response. Furthermore, INM-901-treated AD groups achieved a statistically significant improvement in certain behavior criteria in comparison to the placebo-treated AD groups. These results not only supported but in several instan...